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Summary Thirty-four previously untreated patients with extensive small cell lung cancer were treated with a
combination of carboplatin 300mgm-2 i.v. on day 1 and etoposide 100mgm-2 i.v. on days 1, 2 and 3 every
28 days. Thirty-two patients were assessable for response. Eighteen patients (56%) achieved an objective
response (95% confidence limits 38%-73%). Five (16%) had a complete response and 13 (41.0%) had a
partial response. The median time to response was 7.8 weeks and the median duration of response was 23.1
weeks (range 6.2 to 54 weeks). The median survival of all 34 extensive disease patients was 34.7 weeks (range
1.3-59.3 weeks). Myelosuppression (leukopenia) was the main toxicity. There was one early death that may
have been treatment-related. Biochemical renal dysfunction was noted in two patients. Paresthesiae and
tinnitus/hearing loss were described by three and two patients respectively. Serious gastrointestinal toxicity
was infrequent.
This and other studies have shown this combination to be active and well tolerated in small cell lung
cancer; however, it is not yet clear if it is as efficacious as the more commonly used VP-16-cisplatin regimen.
The combination of VP-16 and cisplatin has proven to be an
active chemotherapy regimen against small cell lung cancer
(SCLC) that has failed primary therapy with cyclo-
phosphamide, adriamycin and vincristine (CAV) (Evans et
al., 1985; Porter et al., 1985). As first-line therapy, it is
highly effective in those who cannot tolerate an adriamycin-
based chemotherapy program (Evans et al., 1985) and as a
primary induction therapy (Sierocki et al., 1985; Woods &
Levi, 1984). The explanation for this clinical activity may
relate to the synergy observed in some animal tumour
systems (Schabel et al., 1979; Von Hoff & Elson, 1980). The
toxicity from the cisplatin component of the regimen
includes nausea and vomiting in a substantial number of
patients and occasional nephrotoxicity which may lead to
discontinuation of therapy (Evans et al., 1985).
Carboplatin (cis-diammine 1,1-cyclobutane dicarboxylate
Pt (II), JM-8, CBDCA, NSC 241240) is a clinically active
cisplatin analogue which is less emetogenic and appears to
be without significant nephrotoxicity, neurotoxicity or oto-
toxicity (Calvert et al., 1982; Canetta et al., 1985). In fact,
carboplatin can be given in the presence of renal functional
impairment if appropriate dose adjustments are made
(Egorin et al., 1984). In Phase I clinical trials, myelo-
suppression, especially thrombocytopenia was dose-limiting
(Calvert et al., 1982; Canetta et al., 1985). Smith et al. (1985)
observed a 41% response rate in a Phase II trial in limited
and extensive small cell lung cancer in which carboplatin was
given as a single intravenous dose of 300-400mgm-2 every
four weeks. Of the 30 previously untreated patients, 18
(60%) responded, including three (10%) complete
remissions.
The same group recently reported on the efficacy of the
combination of VP-16 and carboplatin (Smith et al., 1987).
A high overall response rate (85%) was observed. However,
the median response duration for extensive disease patients
was only 5.5 months and the median survival was 9.5
months.
Bishop et al. (1987) using a different dose and schedule of
VP-16 and carboplatin, have also observed a high frequency
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of response, and survival comparable to standard regimens
in extensive small cell lung cancer.
This report from the National Cancer Institute of Canada
extends these observations on the VP-16-carboplatin combi-
nation in patients with previously untreated extensive small
cell lung cancer.
Patients and methods
Patients were eligible for the study if they had histologic or
cytologic proof of small cell lung cancer and evidence of
extensive disease as defined by spread beyond the primary
site, mediastinum, and ipsilateral supraclavicular nodes.
Patients had to have measurable disease and a performance
status of 0, 1 or 2 on the ECOG performance status scale.
Only patients who had had no prior chemotherapy were
eligible for the study. Prior radiation for symptom palliation
was permitted.
Patients were not eligible for the study if they had central
nervous system metastases at presentation, a baseline
granulocyte count <2.0 x 109cells 1 - or a platelet count
<125x 109 cellsl-, a bilirubin >20 imoll-I or a serum
creatinine > 130pmol 1 -1. Patients had to be less than 80
years of age. All patients had to be accessible for treatment
and follow-up and give written informed consent.
Pretreatment evaluation
All patients had complete blood counts, serum urea, creati-
nine, urinalysis, liver function tests and a chest X-ray and
electrocardiogram prior to entry on the study. In addition,
all patients had an imaging examination of the liver (ultra-
sound, CT or radionuclide scan), a bone scan and a brain
scan (CT or radionuclide scan). Bone marrow aspiration and
biopsy was not routinely performed unless other staging
procedures for extensive disease were negative.
Clinical tumour measurements, haematology and bio-
chemistry were carried out day 1 of each treatment cycle.
Haematology was repeated mid-cycle to estimate nadir
counts. Chest X-rays were repeated day 1 of each treatment
cycle and other radiologic studies were carried out every
other treatment cycle to follow known disease. These studies
were also repeated when patients came off study.
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Treatment plan
Patients were initially treated with VP-16 100mgm-2 days 1,
2 and 3 and carboplatin 300mgm-2 on day 1 only. Carbo-
platin was supplied by the Investigational Drug Branch of
the Division of Cancer Treatment, National Cancer Institute,
Bethesda, Maryland. Because Phase I studies demonstrated
significant prolonged myelosuppression with carboplatin, a
28 day treatment schedule was chosen for this study. A total
of 6 treatment cycles were administered depending on
tumour response and doses of drugs were modified based on
treatment day counts and patient tolerance. VP-16 was
infused (i.v.) over 30 to 60min in either 5% dextrose and
water or normal saline to achieve a concentration of
0.4mgml-l or less. Carboplatin was diluted in a volume of
100ml of 5% dextrose and water and infused i.v. over 20 to
30 minutes.
The doses of both drugs were reduced by 25% for a nadir
granulocyte count <0.2 x 109 1-1 or a treatment day count
of <2.0 x 109 1-1. A 50% dose reduction was to be made for
a nadir platelet count <50 x 1091-1.
To reduce nausea and vomiting, it was recommended that
patients receive a combination of prochlorperazine 10mg
prior to chemotherapy and q6h during treatment in addition
to dexamethasone 10mg i.v. and lorazepam 1-2mg sub-
lingual prior to each course of chemotherapy.
Prophylactic whole brain radiation using 20Gy midplane
dose in five fractions over one week was administered at the
completion of the 6 chemotherapy treatments to all respond-
ing patients.
Response and toxicity
Tumour response was defined according to standard criteria.
Complete response (CR) required the disappearance of all
clinical, radiologic and biochemical evidence of disease for a
minimum of four weeks from the time response was docu-
mented. Partial response (PR) was defined as a greater than
50% decrease in the sum of the products of measured lesions
of at least four weeks duration. During this time, no
simultaneous increase in the size of any lesion or the
appearance of new lesions could occur. Progressive disease
was the unequivocal increase by at least 25% in size of any
measured lesion or the appearance of new lesions. Response
duration was the interval from the first evidence of response
until disease progression. Survival was measured from the
date of first treatment until death or last follow-up.
Patients who achieved a CR or PR were to receive six
courses of therapy and then have treatment stopped. Patients
who showed no change after three courses of VP-16-
carboplatin and those patients whose disease progressed on
the combination were to be changed to alternative systemic
chemotherapy. It was recommended that investigators use
cyclophosphamide, adriamycin and vincristine (CAV) in
order to obtain additional information concerning the cross-
resistance between these two chemotherapy regimens. Toxi-
city was graded according to standard National Cancer
Institute (US) criteria. The protocol was approved by the
Ethics Review Committee of each of the participating
institutions.
Statistical methods
The product limit (Kaplan-Meier) method was used to
estimate the survival distribution.
Results
A total of 37 patients with extensive small cell lung cancer
were entered on the study between December 1985 and
October 1986. Three patients were ineligible for the study:
two had squamous histology on pathology review and one
had no measurable disease. Of the 34 eligible patients, the
majority were males (Table I). The median age was 66 (range
37 to 76) years and 68% of patients had an ECOG
Table I Patient characteristics (n=34)
Median age (years)
Range
66
37-76
No. of
patients
9
25
Sex
Female
Male
Performance status (ECOG)
0
2
Number of sites of tumour involvement
1
2
3
4+
Sites of disease
Liver
Bone
Bone marrow
Adrenal
Lymph nodes
Kidney
2
21
11
2
13
12
7
21
8
3
3
19
1
performance status of 0 or 1. No patient had received any
prior chemotherapy but one patient had been treated with
radiotherapy to the dorsal spine for painful metastatic
lesions. The sites of extrathoracic spread are listed in Table
I. Most patients had multiple sites of extrathoracic spread.
A total of 141 treatment cycles were administered. The
median number of treatment cycles was 4.5: 15 patients
received 6 cycles, two 5 cycles, three 4 cycles, six 3 cycles,
three 2 cycles, and five 1 cycle only. Of those who received
only one treatment cycle, 2 had disease progression, one
refused further treatment, one failed to return to clinic and
there was one early death.
Response
Of the 34 eligible patients, 32 are assessable for response. Of
the two patients who were not assessable for response, one
died day 10 of an apparent cardiac event and one was lost to
follow-up after a single treatment. Five (16%) achieved a
complete response, and 13 (41%) had a partial response for
an overall response rate of 56% (95% confidence limits
38%-73%). Stable disease was observed in six patients
(19%) and disease progression occurred in 8 (25%). Res-
ponse was usually evident within two to three treatment
cycles. The median time to any response was 7.8 weeks
(range 3.8 to 16.1 weeks). This was not significantly different
from the time to best response (8.5 weeks; range 3.9-21).
For the 18 responding patients, the median duration of
response was 23.1 weeks with a range of 6.2 weeks to 54
weeks. The median survival was 32.4 weeks (range 1.3-59.3
weeks) with a projected one year survival of 5%. At the time
of this report, the minimum follow-up is in excess of 40
weeks. Twenty-five (73%) patients have died. Of the 18
responding patients, 6 patients are alive and in remission.
Twelve patients have relapsed and of these five are alive with
disease.
Toxicity
In 108 (76.6%) of the 141 treatment cycles, carboplatin was
given in a dose of 290-300mgm 2. Twenty-seven cycles
(19.1%) were at the reduced dose of 220-250mgm-2 and six
(4%) were at doses <220mgm2.
The most common reason for dosage reduction was
neutropaenia (Table II). Thirty-five of 74 (47%) evaluable
cycles at the starting dose level had a granulocyte count
<1.0x l091-1 and 49 (66%) had a granulocyte count
<1.5 x 1091 l1. The extent of myelosuppression seen with
second or subsequent treatment cycles in those patients who
required a dosage reduction is also evident from Table II.466 W.K. EVANS et al.
Table II Haematologic toxicity to VP-16-carboplatin
Median Median
nadir neutrophils nadir platelets
No. x 1091-1 x 1091-1
Dose level evaluablea (range) (range)
Carboplatin 74 1.15 147
290-300mgm 2 (0.12-3.2) (8-411)
VP-16 lOOmgm-2
Carboplatin 18 0.84 140
220-250mgm2 (0.26-2.3) (23-274)
Carboplatin 4 1.3 187
<220mgmM2 (0.31-2.8) (135-253)
aAn evaluable course is one in which scheduled mid-cycle counts were performed (days 13-17 inclusive).
Only three febrile episodes were encountered. Thrombocyto-
paenia was seen less frequently. Only 6 of 74 (8%) evaluable
treatment cycles had a platelet count below 50 x 1091-1.
As shown in Table III, the proportion of patients who
received 100% of the planned carboplatin and VP-16 doses
decreased with successive treatment cycles. The obvious
implication is that there was cumulative myelosuppression
that prevented the administration of 100% of planned doses
through the six cycles of chemotherapy.
As only one mid-cycle blood count (usually day 15 to 17)
was required by the protocol, an accurate median time to
nadir neutropenia or thrombocytopenia cannot be stated.
Anaemia requiring blood transfusion occurred in one patient
only.
Only 11 of the 141 treatment cycles were delayed. In most
cases, delays were patient initiated for reasons of conven-
ience and were brief in duration. One treatment was delayed
for recovery from a neutropenia-associated infection. A
second delay was necessitated by a herpes zoster infection.
Details of non-haematologic toxicity are given in Table
IV. In general, treatment was well tolerated. Some degree of
nausea and vomiting was described in 27 of 34 patients
(79%), but required fluid replacement in addition to paren-
teral antiemetics in only 3 patients (9%). It should be noted,
Table III Proportion of patients receiving 100% of prescribed
starting doses of VP-16 and carboplatin
Total Percentage receiving
no. of 100% dose
Cycle no. patients both drugs
1 34 94.1
2 29 72.4
3 26 69.2
4 20 60.0
5 17 52.9
6 15 73.3
Table IV Non-haematologic toxicity
Grade
1 2 3 4 5 Total
Alopecia 6 6 5 - - 17
Altered taste 1 1 - - - 2
Anorexia 6 - - - - 6
Confusion/dizziness 2 - 1 - - 3
Hypotension - - - - 1 la
Nausea/vomiting 16 8 3 - - 27
Paraesthesia 3 - - - - 3
Renal 1 1 - - - 2
Shortness of breath - - - - 1 la
Stomatitis 3 1 - - - 4
Tinnitus/hearing loss 2 - - - - 2
Weakness 2 - 1 - - 3
No toxicity 2
aOne patient died day 10 of cycle 1 with renal dysfunction,
pancytopenia and possible congestive heart failure.
however, that all patients received combination antiemetic
therapy with each course of therapy. Post-chemotherapy
anorexia was reported by only six patients. Two patients had
a greater than 20% increase in their serum creatinine above
baseline. The serum creatinine rose to 282pmoll-1 in the
patient who died day 10 of either pulmonary embolus or
myocardial infarct. It was unclear if his chemotherapy
played a role in his sudden illness and renal dysfunction. The
second patient had a rise from a baseline of 99pmollP1 to
138pmoll-1 on day 1 of the sixth cycle of chemotherapy.
The reason for this rise in serum creatinine late in the
treatment course was unclear but it subsequently returned to
normal and is presumed to have been treatment related.
Four additional patients had their serum creatinine rise by
more than 20% but the maximum serum creatinine did not
exceed the upper limit of normal values. Two patients had
mild hearing impairment: one complained of hearing loss but
hearing was not formally tested; a second patient had mild
intermittent tinnitus for cycles 1 and 2. Three patients
reported mild paresthesiae in their distal extremities.
An analysis of response rate by known prognostic factors
(Seifter & Ihde, 1988) including number of sites of tumour
involvement, performance status, liver metastases and LDH
level failed to reveal any significant differences.
Only four of the 14 patients who failed to respond to VP-
16-carboplatin, were treated with second-line chemotherapy.
Three received CAV chemotherapy and none responded.
One was treated with VP-16-cisplatin and failed to respond
and subsequent treatment with CAV was also ineffective.
Of the 18 responding patients, 12 have relapsed and seven
received second-line chemotherapy. Six were treated with
CAV: 2 are not evaluable, 3 had progressive disease and
there was one partial response. Two patients were treated
with VP-16-cisplatin (one after failing CAV): one patient
progressed and the other responded but succumbed to
pneumonia two months after his relapse from first-line
treatment.
Discussion
Although a small proportion of patients with limited small
cell lung cancer may be cured with combined modality
approaches in which chemotherapy is the central therapeutic
modality, extensive disease remains an incurable disease with
a median survival time of approximately 7 to 9 months
(Greco et al., 1978). Current investigative strategies for
extensive SCLC include assessment of new agents as first line
therapy, regimens designed to more effectively utilize existing
cytotoxic agents and efforts to minimize the toxicity of
agents used as palliative therapy.
As indicated earlier, the combination of VP-16 and cis-
platin is highly active in patients with newly diagnosed or
relapsed disease. Data from a randomized trial by the NCIC
clinical trials group indicate that the incorporation of this
combination in an alternating schedule with standard CAV
(cyclophosphamide, adriamycin, vincristine) improves survi-
val when compared to the use of CAV alone (Evans et al.,VP-16-CARBOPLATIN FOR SCLC 467
1987). However, that trial and others (Porter et al., 1985;
Evans et al., 1985, 1986) documented that a small but
significant number of patients experience important renal
toxicity as a result of the cisplatin therapy. It would
therefore be a useful addition to the oncologist's armamen-
tarium to have an agent with less nephrotoxicity compared
with the parent compound if antitumour activity was not
reduced.
This multicentre study demonstrates that VP-16-
carboplatin is both active and relatively non-toxic. However,
the overall response rate of 56% in extensive disease (CR,
16%; PR 41%) appears inferior to the results reported for
VP-16-cisplatin as first-line therapy. Evans reported a com-
plete response rate of 29% and partial response rate of
58.5% in 17 selected extensive disease patients seen at several
University of Toronto institutions (Evans et al., 1985). When
all studies reporting results of VP-16 and cisplatin as first-
line therapy in extensive small cell lung were reviewed, the
overall response rate was 83% with 29% of patients achiev-
ing CR and 54% a PR (Evans et al., 1986).
Smith et al. have reported that 18 of 24 (75%) extensive
disease patients had a partial response and 3 (13%) had a
complete response in a single institution study using the
same doses and schedule of VP-16 and carboplatin as
reported in this study (Smith et al., 1987). It was noted in
their report that the median duration of response was short
(5.5 months) with a predicted continuing remission rate at
one year of <10%. On the other hand, the median survival
time was 9.5 months. Our results are similar with a median
duration of response of 5.8 months and median survival time
of 8.1 months. It should be noted that these survival times
are comparable to those seen in the large National Cancer
Institute of Canada multicenter trial in extensive small cell
lung cancer (Evans et al., 1987). In that study, the median
survival times were 8.0 and 9.6 months for the standard (6
cycles of CAV) and alternating (CAV alternating with VP-
16-cisplatin for 6 cycles) regimens respectively. In addition,
the median survival time of extensive disease patients receiv-
ing VP-16-cisplatin as first-line therapy ranges from 5.8 to
9 months with a mean of approximately 7 months (Evans
et al., 1987). Although direct comparisons between these
studies cannot be made because of potential differences in
study populations, it is reassuring that the survival of
patients treated with VP-16-carboplatin is not markedly
different from that of other commonly employed strategies.
The results achieved by Smith et al. (1987) were achieved
with a treatment plan of only four treatment cycles although
the median number of treatment cycles actually given was
not stated. We attempted to treat all responding patients
with six treatment cycles; the median number of treatment
cycles for the whole group was 4.5.
Bishop et al. (1987) have also investigated the VP-16-
carboplatin combination in a different dose and schedule.
Carboplatin 100mgm-2 was given on each of the three
treatment days (300mgm-2 per course) with VP-16
120mgm-2 day 1, 2, and 3 (360mgm-2 per course). Their
study included 94 previously untreated patients, 59 of whom
had extensive disease. An attempt was made to give a total
of six treatment courses to all responding patients. Overall, a
median of 5 courses of chemotherapy were given. Nine
percent of the extensive disease patients achieved a complete
response and 49% had a partial response. The median
relapse-free survival was 7.9 months and overall survival for
extensive disease patients was 8.3 months.
Although the response rates in extensive disease patients
have ranged from 56.2% to 88% in these three studies, the
overall survival has been similar (8.1, 8.3, 9.5) and compar-
able to other commonly used first-line therapies.
It is clear that this regimen has a lower level of toxicity
than the VP-16-cisplatin combination. Only 2 of 34 (6%)
patients had elevation of serum creatinine above the upper
limit of normal. In one case, the creatinine elevation
occurred at the time of pancytopenia and possible congestive
heart failure and was probably not directly related to
carboplatin administration. In the other case, the elevation
in creatinine occurred at the time of the sixth treatment cycle
and promptly returned to normal. Nausea and vomiting
occurred infrequently. Although this, in part, was attri-
butable to the aggressive use of combination antiemetic
therapy, only 3 of 32 (9%) patients had sufficient
gastrointestinal upset to necessitate intravenous fluid replace-
ment. Three patients reported mild paresthesiae and two also
complained of transient tinnitus and/or hearing loss, demon-
strating that this platinum analog is not totally devoid of
neurotoxic side effects.
Myelosuppression is the major dose limiting side effect of
this combination. Furthermore, myelosuppression appears to
be cumulative as demonstrated by the fact that the propor-
tion of patients receiving 100% of planned treatment doses
dropped to 60% by cycle 4. In addition, some patients had
severe degrees of marrow suppression even after an initial
dosage reduction. On the other hand, anaemia requiring
transfusion was observed only once in this series, which
appears to be much less frequent than with VP-16-cisplatin.
In a series of 31 patients receiving VP-16 and cisplatin as
first-line therapy, anaemia of 100g1-1 or less occurred in
64% and 32% required one or more blood transfusions
(Evans et al., 1985). Although the single agent data sug-
gested that carboplatin might induce serious thrombocyto-
penia in this combination, thrombocytopenia was generally
mild and not dose-limiting.
Of some concern to several investigators participating in
our study was the four week treatment interval. Against a
disease as kinetically aggressive as small cell lung cancer, this
long interval between treatments, may permit tumour re-
growth. Although we could not document any adverse effect
of this treatment interval from the data forms, a few patients
reported that tumour-related symptoms returned in the week
prior to their scheduled day 28 treatment.
We conclude from our results and those of others that the
VP-16-carboplatin combination is active against extensive
small cell lung cancer and better tolerated than VP-16
combined with cisplatin. Although there may be small
differences between the two regimens in terms of anti-
tumour efficacy, it would take a very large randomized
clinical trial to demonstrate what is probably a small
difference.
The NCI-C Lung Group has recently recommended that
CAV alternating with VP-16-cisplatin be accepted as the new
standard for the treatment of extensive small cell lung cancer
(Evans et al., 1987). However, for older patients with
underlying renal dysfunction or those who would be at risk
from a prehydration fluid challenge, the substitution of
carboplatin for cisplatin in this alternating regimen would
seem a reasonable treatment strategy.
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